Cargando…

The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy

BACKGROUND: Chemoradiotherapy is the recommended treatment for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). This study aimed to determine the impact of age on the survival outcomes and risk of radiation pneumonitis (RP) in patients with unresectable locally advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tao, Bi, Nan, Zhou, Zongmei, Chen, Dongfu, Feng, Qinfu, Liang, Jun, Xiao, Zefen, Hui, Zhouguang, Lv, Jima, Wang, Xin, Deng, Lei, Wang, Wenqing, Liu, Wenyang, Wang, Jianyang, Zhai, Yirui, Wang, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475579/
https://www.ncbi.nlm.nih.gov/pubmed/32944347
http://dx.doi.org/10.21037/jtd-20-2137
_version_ 1783579537228955648
author Zhang, Tao
Bi, Nan
Zhou, Zongmei
Chen, Dongfu
Feng, Qinfu
Liang, Jun
Xiao, Zefen
Hui, Zhouguang
Lv, Jima
Wang, Xin
Deng, Lei
Wang, Wenqing
Liu, Wenyang
Wang, Jianyang
Zhai, Yirui
Wang, Luhua
author_facet Zhang, Tao
Bi, Nan
Zhou, Zongmei
Chen, Dongfu
Feng, Qinfu
Liang, Jun
Xiao, Zefen
Hui, Zhouguang
Lv, Jima
Wang, Xin
Deng, Lei
Wang, Wenqing
Liu, Wenyang
Wang, Jianyang
Zhai, Yirui
Wang, Luhua
author_sort Zhang, Tao
collection PubMed
description BACKGROUND: Chemoradiotherapy is the recommended treatment for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). This study aimed to determine the impact of age on the survival outcomes and risk of radiation pneumonitis (RP) in patients with unresectable locally advanced NSCLC. METHODS: The data of patients with unresectable locally advanced NSCLC who were treated with radiotherapy (RT), sequential chemoradiotherapy, or concurrent chemoradiotherapy between January, 2013, and December, 2017, in our institution were retrospectively reviewed and analyzed. Student’s t-test and χ(2) test were used to evaluate the differences between groups divided by optimal cutoff. Survival rates were calculated using the Kaplan-Meier method, and multivariate cox regression was performed to determine the prognostic factors for survival outcomes. RESULTS: A total of 749 patients were included in this analysis. Based on the optimal cutoff, the patients were stratified into two age groups: <65 years old (the younger group, n=482) and ≥65 years old (the older group, n=267). The older group had more patients with poor Karnofsky Performance Score (KPS), squamous cell sarcoma (SCC), and IIIA stage than the younger group. The older patients were more likely to have received RT alone (40.1%) and less likely to have received concurrent chemoradiotherapy (cCRT) (26.6%) than the younger patients (8.1% and 54.8%, respectively, P<0.001). The median overall survival (OS) was 33 months (95% CI: 29–37 months) and 21 months (95% CI: 18–27 months) for the younger group and the older group, respectively (P<0.001). Multivariate Cox regression analysis showed that age had a significant independent association with OS (HR, 1.25; 95% CI: 1.01–1.55) after adjustment for covariates. The incidences of RP, symptomatic RP, and severe RP were similar between the two groups, but the incidence of fatal RP was higher in the older group (4.5% vs. 1.7%, P=0.039). CONCLUSIONS: The clinical characteristics of the older patients in our study differed from those of the younger patients, and the older patients were more likely to choose conservative treatment. OS was longer in the older patients and more cases of fatal RP occurred in the older group.
format Online
Article
Text
id pubmed-7475579
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-74755792020-09-16 The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy Zhang, Tao Bi, Nan Zhou, Zongmei Chen, Dongfu Feng, Qinfu Liang, Jun Xiao, Zefen Hui, Zhouguang Lv, Jima Wang, Xin Deng, Lei Wang, Wenqing Liu, Wenyang Wang, Jianyang Zhai, Yirui Wang, Luhua J Thorac Dis Original Article BACKGROUND: Chemoradiotherapy is the recommended treatment for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). This study aimed to determine the impact of age on the survival outcomes and risk of radiation pneumonitis (RP) in patients with unresectable locally advanced NSCLC. METHODS: The data of patients with unresectable locally advanced NSCLC who were treated with radiotherapy (RT), sequential chemoradiotherapy, or concurrent chemoradiotherapy between January, 2013, and December, 2017, in our institution were retrospectively reviewed and analyzed. Student’s t-test and χ(2) test were used to evaluate the differences between groups divided by optimal cutoff. Survival rates were calculated using the Kaplan-Meier method, and multivariate cox regression was performed to determine the prognostic factors for survival outcomes. RESULTS: A total of 749 patients were included in this analysis. Based on the optimal cutoff, the patients were stratified into two age groups: <65 years old (the younger group, n=482) and ≥65 years old (the older group, n=267). The older group had more patients with poor Karnofsky Performance Score (KPS), squamous cell sarcoma (SCC), and IIIA stage than the younger group. The older patients were more likely to have received RT alone (40.1%) and less likely to have received concurrent chemoradiotherapy (cCRT) (26.6%) than the younger patients (8.1% and 54.8%, respectively, P<0.001). The median overall survival (OS) was 33 months (95% CI: 29–37 months) and 21 months (95% CI: 18–27 months) for the younger group and the older group, respectively (P<0.001). Multivariate Cox regression analysis showed that age had a significant independent association with OS (HR, 1.25; 95% CI: 1.01–1.55) after adjustment for covariates. The incidences of RP, symptomatic RP, and severe RP were similar between the two groups, but the incidence of fatal RP was higher in the older group (4.5% vs. 1.7%, P=0.039). CONCLUSIONS: The clinical characteristics of the older patients in our study differed from those of the younger patients, and the older patients were more likely to choose conservative treatment. OS was longer in the older patients and more cases of fatal RP occurred in the older group. AME Publishing Company 2020-08 /pmc/articles/PMC7475579/ /pubmed/32944347 http://dx.doi.org/10.21037/jtd-20-2137 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhang, Tao
Bi, Nan
Zhou, Zongmei
Chen, Dongfu
Feng, Qinfu
Liang, Jun
Xiao, Zefen
Hui, Zhouguang
Lv, Jima
Wang, Xin
Deng, Lei
Wang, Wenqing
Liu, Wenyang
Wang, Jianyang
Zhai, Yirui
Wang, Luhua
The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
title The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
title_full The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
title_fullStr The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
title_full_unstemmed The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
title_short The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
title_sort impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475579/
https://www.ncbi.nlm.nih.gov/pubmed/32944347
http://dx.doi.org/10.21037/jtd-20-2137
work_keys_str_mv AT zhangtao theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT binan theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT zhouzongmei theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT chendongfu theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT fengqinfu theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT liangjun theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT xiaozefen theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT huizhouguang theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT lvjima theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangxin theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT denglei theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangwenqing theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT liuwenyang theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangjianyang theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT zhaiyirui theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangluhua theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT zhangtao impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT binan impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT zhouzongmei impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT chendongfu impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT fengqinfu impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT liangjun impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT xiaozefen impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT huizhouguang impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT lvjima impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangxin impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT denglei impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangwenqing impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT liuwenyang impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangjianyang impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT zhaiyirui impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy
AT wangluhua impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy